Showing results (131-140 of 147) with videos related to
Sort By:
Pageof 15
British Journal of Cancer|December 3, 2009
Lack of association between oestrogen receptor polymorphisms and change in bone mineral density with tamoxifen therapyN L Henry, A Nguyen, F Azzouz, et al.Clinical Pharmacology and Therapeutics|October 7, 2011
Plasma letrozole concentrations in postmenopausal women with breast cancer are associated with CYP2A6 genetic variants, body mass index, and ageZ Desta, Y Kreutz, A T Nguyen, et al.The Pharmacogenomics Journal|August 24, 2016
Polymorphisms in drug-metabolizing enzymes and steady-state exemestane concentration in postmenopausal patients with breast cancerD L Hertz, K M Kidwell, N J Seewald, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 3, 2018
Impact of homologous recombination deficiency biomarkers on outcomes in patients with triple-negative breast cancer treated with adjuvant doxorubicin and cyclophosphamide (SWOG S9313)P Sharma, W E Barlow, A K Godwin, et al.The Pharmacogenomics Journal|May 8, 2009
Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patientsJ M Rae, M J Sikora, N L Henry, et al.Nature Medicine|December 1, 1996
Breast cancer-associated antigen, DF3/MUC1, induces apoptosis of activated human T cellsC D Gimmi, B W Morrison, B A Mainprice, et al.Journal of the National Cancer Institute|October 16, 1996
Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markersD F Hayes, R C Bast, C E Desch, et al.Clinical Pharmacology and Therapeutics|August 24, 2007
Estrogen receptor genotypes, menopausal status, and the lipid effects of tamoxifenN I Ntukidem, A T Nguyen, V Stearns, et al.Archives of Pathology & Laboratory Medicine|July 11, 2000
Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999P L Fitzgibbons, D L Page, D Weaver, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 13, 2022
Risk-adapted modulation through de-intensification of cancer treatments: an ESMO classificationD Trapani, M A Franzoi, H J Burstein, et al.Pageof 15